Otorhinolaryngology

A topic in the Science corpus, drawn from 478 papers.

Trusted voices in Otorhinolaryngology

Ordered by the trust Otorhinolaryngology's own network concentrates on each researcher, most first.

  1. Søren Bentzen — trusted by 4 researchers here
  2. Kunio Doi — trusted by 3 researchers here
  3. L. Hall-Stoodley — trusted by 2 researchers here
  4. P. Stoodley — trusted by 2 researchers here
  5. W. Craig — trusted by 2 researchers here
  6. N. Brody — trusted by 1 researcher here
  7. Vera Mann — trusted by 2 researchers here
  8. K. Gulabivala — trusted by 2 researchers here
  9. Y. Ng — trusted by 2 researchers here
  10. M. Gillison — trusted by 2 researchers here
  11. R. Biggar — trusted by 2 researchers here
  12. J. Goedert — trusted by 2 researchers here

Most-cited papers in Otorhinolaryngology

Ordered by the recorded citation count from the source corpus; a citation is not an endorsement.

  1. Epidemiologic classification of human papillomavirus types associated with cervical cancer. (2003, New England Journal of Medicine) — 6,445 citations
  2. Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer (2010, New England Journal of Medicine) — 5,857 citations
  3. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. (2006, New England Journal of Medicine) — 5,083 citations
  4. Global epidemiology of oral and oropharyngeal cancer. (2009, Oral Oncology) — 3,448 citations
  5. Platinum-based chemotherapy plus cetuximab in head and neck cancer. (2008, New England Journal of Medicine) — 3,370 citations
  6. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. (2000, Journal of the National Cancer Institute) — 3,171 citations
  7. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. (2004, New England Journal of Medicine) — 3,023 citations
  8. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. (2009, Radiotherapy and Oncology) — 2,996 citations
  9. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. (2004, New England Journal of Medicine) — 2,975 citations
  10. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. (2003, New England Journal of Medicine) — 2,970 citations
  11. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. (2020, Rhinology) — 2,867 citations
  12. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. (2008, Journal of the National Cancer Institute) — 2,711 citations
  13. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck (2016, New England Journal of Medicine) — 2,648 citations
  14. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3… (2019, The Lancet) — 2,572 citations
  15. J OURNAL OF C LINICAL O NCOLOGY Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States (2014) — 2,560 citations
  16. Antimicrobial Treatment Guidelines for Acute Bacterial Rhinosinusitis (2004, Otolaryngology Head & Neck Surgery) — 2,451 citations
  17. Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review (2005, Cancer Epidemiology, Biomarkers and Prevention) — 2,314 citations
  18. Prognosis of Cerebral Vein and Dural Sinus Thrombosis: Results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) (2004, Stroke) — 2,306 citations
  19. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data (2000, The Lancet) — 2,306 citations
  20. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children (2000, The Pediatric Infectious Disease Journal) — 2,244 citations
  21. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. (2012, Rhinology) — 2,203 citations
  22. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. (2015, The Lancet Oncology) — 2,170 citations
  23. Head and neck squamous cell carcinoma (2020, Nature Reviews Disease Primers) — 2,075 citations
  24. World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours (2006, Ear, nose, & throat journal) — 2,031 citations
  25. Worldwide burden of cancer attributable to HPV by site, country and HPV type (2017, International Journal of Cancer) — 2,030 citations
  26. Capecitabine and oxaliplatin for advanced esophagogastric cancer. (2008, New England Journal of Medicine) — 1,984 citations
  27. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. (2010, The Lancet Oncology) — 1,955 citations
  28. A controlled trial of a human papillomavirus type 16 vaccine. (2002, New England Journal of Medicine) — 1,817 citations
  29. HPV-associated Head and Neck Cancer: A Virus-related Cancer Epidemic – A Review of Epidemiology, Biology, Virus Detection and Issues in Management (2010, The Lancet Oncology) — 1,776 citations
  30. Sarcoidosis (2014, The Lancet) — 1,712 citations
  31. Clinical practice guidelines for the prevention and treatment of cancer therapy–induced oral and gastrointestinal mucositis (2004, Cancer) — 1,703 citations
  32. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. (2003, Journal of Clinical Oncology) — 1,689 citations
  33. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) (2005, Head and Neck) — 1,688 citations
  34. Nomenclature and classification of potentially malignant disorders of the oral mucosa. (2007, Journal of Oral Pathology & Medicine) — 1,673 citations
  35. Head and neck squamous cell carcinoma (2020, Nature Reviews Disease Primers) — 1,651 citations
  36. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. (2010, Journal of Infectious Diseases) — 1,633 citations
  37. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. (2007, New England Journal of Medicine) — 1,627 citations
  38. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. (2006, The Lancet) — 1,626 citations
  39. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. (2011, The Lancet Oncology) — 1,613 citations
  40. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial (2011, The Lancet Oncology) — 1,607 citations
  41. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. (2007, New England Journal of Medicine) — 1,599 citations
  42. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. (2014, The Lancet) — 1,597 citations
  43. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised… (2009, The Lancet) — 1,578 citations
  44. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. (2008, Journal of the National Cancer Institute) — 1,568 citations
  45. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. (2008, Journal of Clinical Oncology) — 1,562 citations
  46. Clinical features and prognostic factors in adults with bacterial meningitis. (2004, New England Journal of Medicine) — 1,559 citations
  47. Newborn hearing screening--a silent revolution. (2006, New England Journal of Medicine) — 1,540 citations
  48. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. (2016, The Lancet Oncology) — 1,531 citations
  49. Psychometric validity of the 22‐item Sinonasal Outcome Test (2009, Clinical Otolaryngology) — 1,503 citations
  50. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. (2001, New England Journal of Medicine) — 1,479 citations

Most active researchers

By papers in this topic: a volume measure, not trust.